Antibody-based therapy of human leukemia
Authors:
- Eneida R. NemecekENEneida R. Nemecek
- Dana C. MatthewsDMDana C. Matthews
- 1 July 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 9 (4) , 316-321
Abstract
During the past decades, monoclonal antibodies have been used as vehicles to deliver targeted therapy to sites of leukemic involvement. Anti-CD33 antibodies have been used alone—and more effectively, attached to chemotherapy agents or radioisotopes—to treat those with acute myeloid leukemia. Anti-CD45 antibodies have demonstrated an antileukemic effect when used either unconjugated or attached to radioactive iodine. Antibodies reactive with the myeloid antigen CD66 have been used to deliver targeted radiation to hematopoietic tissues in patients with advanced myeloid malignancies. Antibodies reactive with CD52 and CD20 antigens have been studied for the management of B-cell leukemia. This article reviews the most current clinical trials using monoclonal antibodies in the management of leukemia.Keywords
This publication has 31 references indexed in Scilit:
- Comparison of idarubicin + ara-C–, fludarabine + ara-C–, and topotecan + ara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsBlood, 2001
- Tumor Therapy with Targeted Atomic NanogeneratorsScience, 2001
- High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1HBlood, 2001
- Rituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood, 2001
- Rhenium 188–labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II studyBlood, 2001
- Current use and future development of gemtuzumab ozogamicinSeminars in Hematology, 2001
- Adult Acute Lymphocytic Leukemia: Future Research DirectionsHematology/Oncology Clinics of North America, 2001
- Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemiaBone Marrow Transplantation, 2001
- Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experienceBone Marrow Transplantation, 2000
- A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trialBritish Journal of Haematology, 1999